Literature DB >> 28049746

The global agenda for the prevention of type 2 diabetes.

William H Herman1.   

Abstract

Diabetes represents an enormous and growing clinical and public health problem. Its financial burden is huge and growing and likely to be unsustainable. Lifestyle interventions are safe and effective for preventing diabetes, are associated with improved quality of life, and are cost-effective. Metformin is effective, safe, and cost-effective, if not cost-saving. National and international efforts are needed to identify at-risk individuals and to systematically apply these interventions. Research must focus on how best to implement diabetes prevention in diverse populations and settings.
© The Author(s) 2016. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cost; cost-effectiveness; diabetes; prevention

Mesh:

Substances:

Year:  2017        PMID: 28049746      PMCID: PMC5207005          DOI: 10.1093/nutrit/nuw034

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  38 in total

1.  Global healthcare expenditure on diabetes for 2010 and 2030.

Authors:  Ping Zhang; Xinzhi Zhang; Jonathan Brown; Dorte Vistisen; Richard Sicree; Jonathan Shaw; Gregory Nichols
Journal:  Diabetes Res Clin Pract       Date:  2010-02-19       Impact factor: 5.602

2.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

Authors:  A Ramachandran; C Snehalatha; S Mary; B Mukesh; A D Bhaskar; V Vijay
Journal:  Diabetologia       Date:  2006-01-04       Impact factor: 10.122

3.  Redesigning employee health incentives--lessons from behavioral economics.

Authors:  Kevin G Volpp; David A Asch; Robert Galvin; George Loewenstein
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

4.  The rising global burden of diabetes and its complications: estimates and projections to the year 2010.

Authors:  A F Amos; D J McCarty; P Zimmet
Journal:  Diabet Med       Date:  1997       Impact factor: 4.359

5.  The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.

Authors:  V R Aroda; C A Christophi; S L Edelstein; P Zhang; W H Herman; E Barrett-Connor; L M Delahanty; M G Montez; R T Ackermann; X Zhuo; W C Knowler; R E Ratner
Journal:  J Clin Endocrinol Metab       Date:  2015-02-23       Impact factor: 5.958

6.  The Diabetes Prevention Program (DPP): description of lifestyle intervention.

Authors: 
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

7.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

8.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Authors:  Jaana Lindström; Pirjo Ilanne-Parikka; Markku Peltonen; Sirkka Aunola; Johan G Eriksson; Katri Hemiö; Helena Hämäläinen; Pirjo Härkönen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Paturi; Jouko Sundvall; Timo T Valle; Matti Uusitupa; Jaakko Tuomilehto
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

9.  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

Authors:  Ryuzo Kawamori; Naoko Tajima; Yasuhiko Iwamoto; Atsunori Kashiwagi; Kazuaki Shimamoto; Kohei Kaku
Journal:  Lancet       Date:  2009-04-22       Impact factor: 79.321

10.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

View more
  4 in total

Review 1.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

2.  Derivation and Validation of a Prediction Model for Predicting the 5-Year Incidence of Type 2 Diabetes in Non-Obese Adults: A Population-Based Cohort Study.

Authors:  Xin-Tian Cai; Li-Wei Ji; Sha-Sha Liu; Meng-Ru Wang; Mulalibieke Heizhati; Nan-Fang Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-11       Impact factor: 3.168

3.  Potential adverse effects of botanical supplementation in high-fat-fed female mice.

Authors:  Scott Fuller; Yongmei Yu; Tamra Mendoza; David M Ribnicky; William T Cefalu; Z Elizabeth Floyd
Journal:  Biol Sex Differ       Date:  2018-09-12       Impact factor: 5.027

4.  Diabetes knowledge among non-diabetic hypertensive patients in Calabar, Nigeria.

Authors:  Ofem Egbe Enang; Ogban Ezukwa Omoronyia; Agam Ebaji Ayuk; Kenneth Nnachetam Nwafor; Anette Oshioagiemhe Legogie
Journal:  Pan Afr Med J       Date:  2020-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.